Lexicon Pharmaceuticals Reports 2nd Quarter Financial Results, Provides Clinical Pipeline Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
JPMorgan Downgrades Lexicon Pharmaceuticals (LXRX) to Neutral
August 10, 2015 6:45 AM EDTJPMorgan downgraded Lexicon Pharmaceuticals (NASDAQ: LXRX) from Overweight to Neutral with a price target of $14.00 (from $9.00).
For an analyst ratings summary and ratings history on Lexicon Pharmaceuticals click here. For more ratings news on Lexicon Pharmaceuticals click here.
Shares of Lexicon Pharmaceuticals closed at $11.38 yesterday.
... MoreLexicon Pharma (LXRX) Tops Q2 EPS by 5c
August 7, 2015 7:30 AM EDTLexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.27), $0.05 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $376 million versus the consensus estimate of $360 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
... More